A stumbling block on the way to an Alzheimer’s cure
By
Lois A. Bowers
Nov 14, 2022
In a new study, 56% of participants said they were not likely to take part in a trial of a dementia-prevention drug. Senior living may be able to play a role in decreasing that percentage.
Should residents’ access to Alzheimer’s drug be restricted?
By
Lois A. Bowers
Jan 18, 2022
You have until Feb. 10 to share your comments with CMS about its recent proposal related to Alzheimer’s drug aducanumab (Aduhelm).
Health habits’ connection to dementia in the spotlight as new year begins
By
Lois A. Bowers
Jan 04, 2022
An update to the National Plan to Address Alzheimer’s Disease, as well as news of potential treatments and a finding that “astonished” researchers add up to promising news to start the new...
‘Whole concept of senior living will change’ if Alzheimer’s drug is approved
By
Lois A. Bowers
Oct 24, 2019
“The whole concept of senior living will change,” CNBC’s Jim Cramer said Tuesday, discussing the news that Biogen and Eisai plan to seek regulatory approval of their investigational treatment for...
Two Alzheimer’s drug trials halted
By
Lois A. Bowers
Mar 22, 2019
Two late-stage clinical trials of a drug for Alzheimer’s disease have been stopped because they aren’t likely to produce promising results, two companies involved with the research announced Thursday.